HMRlignan (Norway spruce extract)
HMRlignan is a purified form of 7-hydroxymatairesinol (HMR), a plant lignan extracted from Norway spruce (Picea abies) knots, which the gut microbiota converts to the mammalian lignan enterolactone. This enterolactone acts as a selective estrogen receptor modulator (SERM), binding estrogen receptors with weak agonist or antagonist activity depending on the hormonal environment.
Origin & History
HMRlignan is a branded, purified extract from the wood knots of the Norway spruce (Picea abies L.), a coniferous tree native to Europe. Produced by Linnea SA using a special low-environmental-impact process, it yields an off-white crystalline powder standardized to not less than 90% 7-hydroxymatairesinol (HMR) potassium acetate complex.
Historical & Cultural Context
HMRlignan as an isolated compound is a modern nutraceutical discovered in the 1990s-2000s with no direct traditional medicine use. However, lignan-rich plants like flaxseed, sesame, and whole grains have been consumed across cultures for reproductive health, digestive balance, and cardiovascular wellness.
Health Benefits
• Hormone balance support through phytoestrogen activity that modulates estrogen receptors in a protective manner (mechanistic evidence) • Cardiovascular health support through LDL cholesterol reduction and anti-inflammatory effects (observational lignan research) • Potential breast and prostate cancer risk reduction (observational studies on dietary lignans) • Immunomodulatory activity demonstrated in vitro (PMID: 20005303) • Antioxidant protection through conversion to enterolactone metabolites (mechanistic evidence)
How It Works
HMRlignan (7-hydroxymatairesinol) is metabolized by intestinal bacteria, primarily Clostridium scindens and related species, into enterolactone, a mammalian lignan with SERM activity. Enterolactone competitively binds estrogen receptors ERα and ERβ with preferential affinity for ERβ, modulating gene transcription in a tissue-selective manner that may limit estrogen-driven cell proliferation. Additionally, enterolactone inhibits aromatase (CYP19A1) enzyme activity, reducing local estrogen biosynthesis, and exerts antioxidant effects by scavenging reactive oxygen species and upregulating Nrf2-mediated antioxidant pathways.
Scientific Research
Clinical evidence for HMRlignan specifically is limited, with only one identified in vitro study (PMID: 20005303) demonstrating immunomodulatory activity. While manufacturers reference upcoming data on anti-inflammatory effects for heart health and enlarged prostate, no completed human RCTs are detailed in current literature. Evidence primarily draws from observational studies on general dietary lignan intake.
Clinical Summary
A randomized, double-blind, placebo-controlled trial in 22 postmenopausal women demonstrated that 36 mg/day of HMRlignan for 8 weeks significantly raised serum enterolactone levels compared to placebo, confirming reliable bioconversion. Observational epidemiological studies associating high enterolactone levels with reduced LDL cholesterol and lower inflammatory markers (CRP) provide indirect cardiovascular evidence, though intervention trials specifically using HMRlignan for lipid outcomes remain limited in size and number. Preclinical and mechanistic data support potential roles in hormone-sensitive cancer risk reduction, but no large-scale RCTs have confirmed this in humans. Overall, evidence for enterolactone elevation is strong; evidence for downstream clinical endpoints such as cardiovascular disease or cancer risk reduction requires larger interventional studies.
Nutritional Profile
{"macronutrients": {"fiber": "Present in trace amounts, specific concentration not well-documented"}, "micronutrients": {"vitamins": "Not a significant source of vitamins", "minerals": "Not a significant source of minerals"}, "bioactive_compounds": {"lignans": "High concentration, primarily 7-hydroxymatairesinol (HMR), typically around 80-90% of total lignans", "phytoestrogens": "Present due to lignan content, contributing to estrogen receptor modulation"}, "bioavailability_notes": "Lignans are metabolized by intestinal bacteria into enterolignans, which are absorbed and exert biological effects. Bioavailability can vary based on gut microbiota composition."}
Preparation & Dosage
No clinically studied dosage ranges are specified for HMRlignan in human trials. The ingredient is standardized to contain not less than 90% HMR potassium acetate complex and is typically formulated in capsules or softgels. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Flaxseed lignans, Green tea extract, Resveratrol, DIM (diindolylmethane), Saw palmetto
Safety & Interactions
HMRlignan is generally well tolerated at doses of 36–72 mg/day, with no serious adverse events reported in short-term clinical studies; mild gastrointestinal discomfort has been noted occasionally. Due to its SERM and aromatase-inhibiting activity, HMRlignan should be used cautiously by individuals taking hormone-sensitive medications, including tamoxifen, aromatase inhibitors (anastrozole, letrozole), or hormone replacement therapy, as pharmacodynamic interactions may alter efficacy. Individuals with estrogen receptor-positive (ER+) cancers should consult an oncologist before use, as the net estrogenic or anti-estrogenic effect in vivo depends on systemic hormone levels. Safety data in pregnancy and lactation are insufficient, and use is not recommended in these populations.